Dilated Perivascular Spaces in the Dentate Nucleus on MRI in Patients with Hypertensive Angiopathy or Cerebral Amyloid Angiopathy

NCT06888882 | Not Yet Recruiting

• 1 other identifier: LOCAL/2025/DR-02
• Study Type: observational
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

Hypertensive arteriopathy (HA) and cerebral amyloid angiopathy (CAA) are the two most common forms of cerebral small vessel disease. On MRI, chronic small vessel disease-related abnormalities include white matter hyperintensities, dilated perivascular spaces (DPVS), lacunar infarction, and hemorrhagic features (e.g. cerebral microbleeds, CMB). In the cerebellum, deep CMB involving the dentate nucleus (DN) is associated with HA, whereas the presence of superficial cerebellar CMB are associated with CAA. DPVS are observed in both diseases, predominant in the subcortical white matter (especially in the centrum semiovale) in CAA whereas HA-related DPVS are predominant deep in the brain inside or nearby the basal ganglia. To the best of our knowledge, DN-DPVS have never been studies systematically in small vessel disease. The researchers want to study DN-DPVS on T2-weighted 3T MRI in patients with HA or CAA and to compare both groups.

Conditions

Hypertensive Arteriopathy; Cerebral Amyloid Angiopathy

Outcome Measures

Primary Outcomes (11)

• Sex

  Comparaison of both populations (HA/CAA), H/F

  baseline

• Hypertension

  history of hypertension (Yes/No)

  baseline

• Age

  Age at time of T2-weighted imaging,

  baseline

• Time

  Time between initial MRI-based CAA/HA diagnosis and 3T T2-weighted imaging, axial or coronal views of T2 imaging,

  baseline

• MRI view

  T2 performed using coronal or axial imaging (axial / coronal

  baseline

• hypercholesterolemia

  history of hypercholesterolemia (Yes/No)

  baseline

• Hemorrhagic lesion

  Hemorrhagic lesion load on T2\*-weighted imaging (ICH and CMB for both CAA and HA, and subarachnoid hemorrhage/cortical superficial siderosis for CAA)

  baseline

• Subcortical lobar DPVS

  Semi-quantitative score for evaluation of subcortical lobar DPVS (0 if DPVS are absent, 1 if 1 to 10 DPVS are visible, 2 for 11 to 20 DPVS, 3 for 21 to 40 DPVS, and 4 for \>40 DPVS).

  baseline

• DPVS of basal ganglia

  Semi-quantitative score for evaluation of DPVS of basal ganglia (0 if DPVS are absent, 1 if 1 to 10 DPVS are visible, 2 for 11 to 20 DPVS, 3 for 21 to 40 DPVS, and 4 for \>40 DPVS).

  baseline

• Diabete

  history of diabetes (Yes/No)

  baseline

• Smoking

  current smoking (Yes / No)

  Baseline

Study Arms (2)

CAA

Patients with cerebral amyloid angiopathy

HA

Patients with Hypertensive arteriopathy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with lobar intracerebral hemorrhage \[ICH\], subarachnoid hemorrhage or cortical superficial siderosis for CAA or basal ganglion ICH for HA

You may qualify if:

• Patient registered in the CHU de Nîmes (France) stroke database with lobar intracerebral hemorrhage \[ICH\], subarachnoid hemorrhage or cortical superficial siderosis for CAA or basal ganglion ICH for HA
• Patient managed at the CHU de Nîmes (France) between 01/1/2015 and 31/12/2024
• Patient with T2-weighted MRI performed with a 3T magnet

You may not qualify if:

• Refusal to participate

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, Occitanie, 3029, France

Location

MeSH Terms

Conditions

Cerebral Amyloid Angiopathy

Condition Hierarchy (Ancestors)

Cerebral Arterial Diseases; Intracranial Arterial Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Amyloidosis; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Anissa MEGZARI

  Centre Hospitalier Universitaire de Nīmes

  STUDY DIRECTOR

Central Study Contacts

Dimitri RENARD, Dr

CONTACT

+33 4.66.68.32.61; dimitri.renard@chu-nimes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2025
• First Posted: March 21, 2025
• Study Start: April 1, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: March 21, 2025

Record last verified: 2025-03

Locations

FR (1)